CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Mallinckrodt

At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines, and active pharmaceutical ingredients. Together, we`re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago – quality, integrity and service. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.

Leiters

Leiters is a FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services. We are committed to providing healthcare professionals and their patients with high quality medications.

Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies. With product candidates in oncology and cardiology, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer. Founded in 2007, Celyad leverages unique know-how in taking cell based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products. Celyad builds it business model on partnering with prominent research institutions such as the Mayo Clinic and Dartmouth College, and develops those programs from bench to commercial applications.

Gala Design Inc

Gala Design Inc is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.